About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Calcipotriol Spray (AKP01) Against Mild to Moderate Plaque Psoriasis in Phase 3 Trial

by Colleen Fleiss on May 11, 2020 at 8:12 PM
Font : A-A+

Calcipotriol Spray (AKP01) Against Mild to Moderate Plaque Psoriasis in Phase 3 Trial

The Board of Lipidor has submitted positive results from the completed Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis.

Discussions with medium and large pharmaceutical companies regarding the licensing, marketing and sale of a product based on AKP01 have been conducted with generally positive feedback and also clear guidance for the company's prioritization going forward (see below).

Advertisement


AKP01 is a so-called "monoproduct", defined by the active substance calcipotriol formulated with Lipidor's unique and patented AKVANO® technology. The market potential of this "combo product" is estimated to be around 3 times greater (USD 580m in 2017*) than that of the monoproduct and also showing significantly higher growth numbers.

*Data from Datamonitor

AKP02 Phase III to be carried out in-house

Lipidor previously announced the intention to conduct a Phase III study of the combo product (AKP02) in collaboration with a licensee. In light of the positive response to the reported Phase III study of AKP01 in particular, and AKVANO technology in general, Lipidor's Board of Directors as decided to carry out this study on its own, fully-funded by available liquid funds and with a planned start of study at the end of 2020/2021.
Advertisement

The Board is of the opinion that AKP02 has excellent prospects for taking significant market share in a large and growing market. With data from a self-financed Phase III study, a large portion of risk is eliminated from the project, implying a significantly higher value for out-licensing at the next stage.

AKP01 continues to be an interesting out-licensing project and partner talks to date have indicated a clear interest in licensing AKP02 in combination with AKP01, with the aim of maximizing penetration of both products in the market. It is also the Board's opinion and the company's objective that commercial agreements regarding a combination license for AKP01 and AKP02 will be concluded within the next 12 months, which would provide further clarity on the products' path to market and future revenue potential for Lipidor.

A general timetable for the planned Phase III study would be as follows:

Q2 2020 - Agreement on start of study

Q3 2020 - Manufacture of clinical trial material

Q1 2021 - First patient in

Q1 2022 - Results of study

Updates concerning AKP03 and AKP07

With the listing of Lipidor's share on Nasdaq First North Growth Market in October 2019, the company announced its aim of entering into a partnership regarding Lipidor's project AKP03, with the active pharmaceutical component of fusidic acid. Lipidor has discussed the project with several potential licensees without being able to conclude an agreement before the outbreak of COVID-19. It remains Lipidor's ambition to identify and enter into a partnership for the project without conducting further clinical studies.

Also in connection with the October 2019 listing, the company announced its objective of initiating a Phase II study of AKP07 (Tacrolimus) for the treatment of atopic dermatitis in the first half of 2020. The project continues according to plan in many aspects, with a focus on formulation optimization and product stability. However, in the light of the reprioritisation made in AKP02, the liquid funds that need to be allocated to the planned Phase III study and minor delays based on the Covid-19 outbreak the timetable for the start of the planned Phase II study for AKP07 is being shifted. The company will return with an updated timetable for the project.

Upcoming projects - collaboration with Cannasure plus OTC products in collaboration with Aurena

In addition to the above projects, Lipidor initiated two strategic partnerships during Q4 2019 and Q1 2020.

In December 2019, Lipidor announced that it had entered into an agreement with the Israeli company Cannassure for a feasibility study with a licensing option, for the development and sale of topical medicinal cannabis products. The project is proceeding according to plan with the aim of being evaluated in Q3 2020.

In the first months of the year, Lipidor has also deepened its cooperation with Aurena Laboratories AB, which is also one of the company's largest shareholders. This latest initiative was prompted by the need for new disinfectant products in the wake of the Covid-19 pandemic. A first product has been launched and is now available for purchase on the Swedish market, while talks are taking place with additional retailers internationally. Discussions are being held with Aurena Laboratories AB about further potential products aimed directly at consumers (so-called "OTC" products). It is the ambition of the companies to return with updates on these discussions later in the year.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Pepper as Preventive Measure Against Omicron
FODMAP Diet: A Beginner's Guide
Smallpox
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Psoriasis Dry Skin Symptom Evaluation Foods that are Bad for your Skin Itchy Scalp Peyronie´s Disease Diet for Psoriasis Scalp Psoriasis Psoriasis Cure with Homeopathy: Fact or Fiction Psoriatic Arthritis Neck Cracking 

Recommended Reading
Diet for Psoriasis
Learn what causes psoriasis, the appropriate diet to follow and the importance of diet in the ......
Psoriasis
Psoriasis is a recurrent and complex inflammatory skin disorder that can have tremendous physical .....
Quiz on Psoriasis
Psoriasis is a non-contagious, non-fatal disease but it can adversely affect one's overall quality ....
Dry Skin Symptom Evaluation
Dry skin a result in inadequate hydration of the skin. This could be either due to a reduced intake...
Foods that are Bad for your Skin
Hydration, sebum formation and skin acidity determine the skin condition. Along with aging and envir...
Neck Cracking
Neck cracking or neck popping is caused by quick movements to loosen the ligaments and joints of the...
Peyronie´s Disease
Peyronie''s disease is caused by scar tissue along the length of the penis, which causes the penis t...
Psoriasis Cure with Homeopathy: Fact or Fiction
Psoriasis, a chronic autoimmune skin disease has phases of exaggeration and remission. Homeopathic r...
Psoriatic Arthritis
Psoriatic arthritis is a kind of autoimmune inflammatory arthritis, which develops in 30 percent of ...
Scalp Psoriasis
Scalp psoriasis, a common skin disorder causes lesions on the scalp. There is no cure for scalp psor...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use